Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma

BAIYONG SHEN

Status: Completed

Conditions: Pancreatic Cancer Resectable

Treatments: Device: Multigene panel for next-generation sequencing

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT05483257

M-Cli200633-PC

Details and patient eligibility

About

Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients.

Enrollment: 226 patients

Sex: All

Ages: 34 to 84 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Radically resected pancreatic adenocarcinoma (stage I-III)
• Resected tumor tissues and matched blood cells available
• Signed informed consent

Exclusion criteria

• Pancreatic cancer except pancreatic adenocarcinoma
• Non-radical resection